NCT06511869 is a Phase 2 clinical trial of AZD4205 in Peripheral T-cell Lymphoma, sponsored by Dizal Pharmaceuticals.

Who is sponsoring NCT06511869?

NCT06511869 is sponsored by Dizal Pharmaceuticals.

What drugs are being tested in NCT06511869?

Interventions in NCT06511869: AZD4205.

What condition does NCT06511869 study?

NCT06511869 studies Peripheral T-cell Lymphoma.

Is NCT06511869 still recruiting?

NCT06511869 is currently completed. Last updated 4 July 2025.

Last reviewed 2025-07-04 · How we verify

NCT06511869

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

Completed Phase 2 Last updated 4 July 2025

What this trial tests

Phase 2 trial testing AZD4205 in Peripheral T-cell Lymphoma in 48 participants. Completed in 31 March 2025.

Timeline

17 March 2022

Primary endpoint
31 March 2025

31 March 2025

Quick facts

Lead sponsor	Dizal Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	17 March 2022
Primary completion	31 March 2025
Estimated completion	31 March 2025
Sites	23 locations across China

Drugs / interventions tested

AZD4205 — full drug profile →

Conditions studied

Peripheral T-cell Lymphoma — all drugs for Peripheral T-cell Lymphoma →

Sponsor

Dizal Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Peripheral T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is intended to assess the safety and anti-tumor activity of AZD4205 at 150 mg once daily in participants with PTCL who have achieved tumor response after first-line systemic therapy (with or without combination radiotherapy) and are ineligible for HSCT assessed by the investigator as ineligible for HSCT or have no plan for HSCT.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma.
Kashyap A, Dai J, Ni X. · · 2025 · cited 3× · PMID 40002165 · DOI 10.3390/cancers17040568
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26).
Wei J, Cai Q, Zhang L, Zou L, et al · · 2026 · PMID 41844573 · DOI 10.1038/s41408-026-01452-8

Verify or expand the search:

Other trials of AZD4205

Trials testing the same drug.

NCT06511895 — AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) · Phase 2 · completed
NCT03728023 — A Study of AZD4205 in Healthy Adult Subjects · Phase 1 · completed
NCT03450330 — Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-sma · Phase 1, PHASE2 · completed

Other recruiting trials for Peripheral T-cell Lymphoma

Currently open trials in the same condition.

NCT07523555 — Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · Phase 1, PHASE2 · recruiting
NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
NCT06914037 — A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies · Phase 1 · recruiting
NCT07072221 — Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients · NA · recruiting
NCT06739265 — Golidocitinib Plus CHOP in Newly Diagnosed PTCL · Phase 1, PHASE2 · recruiting

Other Dizal Pharmaceuticals trials

Trials by the same sponsor.

NCT06813365 — Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2) · Phase 1 · recruiting
NCT07234162 — A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) · Phase 3 · recruiting
NCT06084104 — DZD9008 PK Study in Hepatic Impairment Subjects · Phase 1 · completed
NCT05926180 — Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and · Phase 1 · completed
NCT05824585 — DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06511869 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dizal Pharmaceuticals
Last refreshed: 4 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06511869.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing